アブストラクト
| Title | せん妄への対応 |
|---|---|
| Subtitle | 特集 高齢患者の精神科コンサルテーション・リエゾン (CLP) ; 精神科医が知っておくべき知識Update |
| Authors | 八田耕太郎 |
| Authors (kana) | |
| Organization | 順天堂大学医学部附属練馬病院メンタルクリニック科 |
| Journal | 老年精神医学雑誌 |
| Volume | 33 |
| Number | 1 |
| Page | 18-24 |
| Year/Month | 2022 / 1 |
| Article | 報告 |
| Publisher | ワールドプランニング |
| Abstract | 「抄録」せん妄の診断において重要な点は, 高齢者の不穏がすべて「せん妄」ではないことである. とくに, 認知症患者が入院する場合の極度の不安からの興奮, すなわち認知症に伴う行動・心理症状(BPSD)との鑑別は, 介入方法が異なるため注意深くする必要がある. 非薬物的介入は, DELTAプログラムに代表されるようにすでに実装されている. 一方, 薬物的介入では, せん妄状態の治療には抗精神病薬, 予防にはメラトニン受容体作動薬やオレキシン受容体拮抗薬が鍵となる. |
| Practice | 臨床医学：内科系 |
| Keywords | せん妄, DELTAプログラム, 抗精神病薬, メラトニン受容体作動薬, オレキシン受容体拮抗薬 |
- 全文ダウンロード： 従量制、基本料金制の方共に968円(税込) です。
参考文献
- 1) Agar MR, Lawlor PG, Quinn S, Draper B, et al.: Ef-ficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palli-ative Care ; A Randomized Clinical Trial. JAMA In-tern Med, 177 : 34-42(2017).
- 2) American Geriatrics Society Expert Panel on Post-operative Delirium in Older Adluts : American Ge-riatrics Society abstracted clinical practice guide-line for postoperative delirium in older adults. J Am Geriatr Soc, 63(1) : 142-150(2015).
- 3) American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders, Fifth Edi-tion(DSM-5(R)). American Psychiatric Association, Arlington, VA(2013).
- 4) Devlin JW, Roberts RJ, Fong JJ, Skrobik Y, et al.: Ef-ficacy and safety of quetiapine in critically ill pa-tients with delirium ; A prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med, 38(2) : 419-427(2010).
- 5) Girard TD, Exline MC, Carson SS, Hough CL, et al.; MIND-USA Investigators : Haloperidol and Ziprasi-done for Treatment of Delirium in Critical Illness. N Engl J Med, 379(26) : 2506-2516(2018).
残りの18件を表示する
- 6) Hamasaki MY, Barbeiro HV, Barbeiro DF, Cunha DM, et al.: Neuropeptides in the brain defense against distant ergan damage. J Neuroimmunol, 290 : 33-35(2016).
- 7) 八田耕太郎 : せん妄ハンドブック. 39, 中外医学社, 東京(2021).
- 8) Hatta K, Kishi Y, Wada K, Takeuchi T, et al.; DELIR-IA-J Group : Preventive effects of ramelteon on delirium ; A randomized placebo-controlled trial. JAMA Psychiatry, 71(4) : 397-403(2014).
- 9) Hatta K, Kishi Y, Wada K : Ramelteon for Delirium in Hospitalized Patients. JAMA, 314(10) : 1071-1072(2015).
- 10) Hatta K, Kishi Y, Wada K, Takeuchi T, et al.: Preven-tive Effects of Suvorexant on Delirium ; A Ran-domized Placebo-Controlled Trial. J Clin Psychia-try, 78(8) : e970-e979(2017).
- 11) Hatta K, Kishi Y, Wada K, Takeuchi T, et al.: Real-World Effectiveness of Ramelteon and Suvorexant on Delirium Prevention in 967 Patients With Deliri-um Risk Factors. J Clin Psychiatry, 81(1) : 19m12865(2020).
- 12) Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, et al.: Comparative efficacy and tolera-bility of 32 oral antipsychotics for the acute treat-ment of adults with multi-episode schizophrenia ; A systematic review and network meta-analysis. Lancet, 394(10202) : 939-951(2019).
- 13) Inouye SK, van Dyck CH, Alessi CA, Balkin S, et al.: Clarifying confusion ; The confusion assessment method-A new method for detection of deliri-um. Ann Intern Med, 113(12) : 941-948(1990).
- 14) Inouye SK, Westendorp RG, Saczynski JS : Delirium in elderly people. Lancet, 383(9920) : 911-922(2014).
- 15) Khaing K, Nair BR : Melatonin for delirium preven-tion in hospitalized patients ; A systematic review and meta-analysis. J Psychiatr Res, 133 : 181-190(2021).
- 16) Liguori C, Romigi A, Nuccetelli M, Zannino S, et al.: Orexinergic system dysregulation, sleep impair-ment, and cognitive decline in Alzheimer disease. JAMA Neurol, 71(12) : 1498-1505(2014).
- 17) Maldonado JR : Delirium pathophysiology ; An up-dated hypothesis of the etiology of acute brain fail-ure. Int J Geriatr Psychiatry, 33(11) : 1428-1457(2018).
- 18) Ogawa A, Okumura Y, Fujisawa D, Takei H, et al.: Quality of care in hospitalized cancer patients be-fore and after implementation of a systematic pre-vention program for delirium ; The DELTA explor-atory trial. Support Care Cancer, 27(2) : 557-565(2019).
- 19) Tahir TA, Eeles E, Karapareddy V, Muthuvelu P, et al.: A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. J Psy-chosom Res, 69(5) : 485-490(2010).
- 20) The Scottish Intercollegiate Guidelines Network(SIGN) : SIGN 157 ; Risk Reduction and Manage-ment of Delirium-A national clinical guideline. March 2019. Available at : https://www.sign.ac.uk/media/1423/sign157.pdf
- 21) Trzepacz PT, Maldonado JR, Kean J, Abell M, et al.: Delirium Rating Scale-Revised-98(DRS-R98)Ad-ministration Manual. Electronic edition. Trzepacz PT, USA(2010).
- 22) Xu S, Cui Y, Shen J, Wang P : Suvorexant for the prevention of delirium ; A meta-analysis. Medi-cine(Baltimore), 99(30) : e21043(2020).
- 23) Young J, Murthy L, Westby M, Akunne A, et al.: Di-agnosis, prevention, and management of delirium ; Summary of NICE guidance. BMJ, 341 : c3704(2010).
